Brief: Dr Reddy's Exec Says Elevated Frieght Costs Due To Middle East Issues, High Solvent Prices Impacted EBITDA This Quarter
22/07/2026 14:47
BRIEF-Dr Reddy's Exec Says Elevated Frieght Costs Due To Middle East Issues, High Solvent Prices Impacted EBITDA This Quarter July 22 - Dr Reddy's Laboratories Ltd REDY.NS:
DR REDDY'S EXEC- ELEVATED FRIEGHT COSTS DUE TO MIDDLE EAST ISSUES, HIGH SOLVENT PRICES IMPACTED EBITDA THIS QUARTER
DR REDDY'S EXEC- LAUNCHED GENERIC SEMAGLUTIDE TABLETS IN INDIA
DR REDDY'S EXEC- WORKING TO RESUME SEMAGLUTIDE SUPPLIES AT EARLIEST
DR REDDY'S EXEC ON TARIFF- BEEN IN THESE CYCLES BEFORE, NOT PRACTICAL TO MOVE TO U.S. IMMEDIATELY
DR REDDY'S EXEC ON TARIFF - IF TARIFF IS IMPOSED, WILL RAISE PRICES IN THE U.S.
DR REDDY'S EXEC ON TARIFF - NOT GOING TO DO ANYTHING SPECIAL IMMEDIATELY DUE TO TARIFF ANNOUNCEMENT, WILL ASSESS
Source text: [ID:]
Further company coverage: REDY.NS
Recent news on Dr. Reddy's Laboratories
See all newsDr Reddy's rolls out new generic Ozempic brands to ease Obeda supply hit
Dr Reddy's beats quarterly profit estimate on India market lift (updated)
India's Dr Reddy's beats quarterly profit estimate
Brief: Dr. Reddy's Q2 Consol Net PAT 9.25 Billion Rupees
Dr Reddy's rolls out new generic Ozempic brands amid Obeda supply disruption